Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Endologix, Inc. (ELGX): Deerfield Management Upping its Game

It seems the recent decline in Endologix, Inc. (NASDAQ:ELGX)’s stock by around 20% has made it more lucrative for hedge funds. As a recent filing with Securities and Exchange Commission (SEC) shows, James E. Flynn’s Deerfield Management has increased its stake in the company to over 4.48 million shares from over 1.48million shares that it owned previously. Deerfield now owns a total of 6.7% stake in the company as a passive investor.

Endologix, Inc. (NASDAQ:ELGX)

Deerfield Management is life sciences-focused hedge fund that invests in both publicly traded and private companies. From its humble beginnings in 1994 with $17 million in assets under management, it has now grown to managing over $5 billion. Deerfield invests in companies across the healthcare spectrum from early state drug research start-ups to mature healthcare services and device companies. In the second quarter of 2014, the fund increased its stake significantly in Allergan, Inc. (NYSE:AGN), shares of which are up more than 45% in the last 6 months, and Keryx Biopharmaceuticals (NASDAQ:KERX), which is up more than 10% in last six months and more than 70% year over year. Most of the large holdings of Deerfield have outperformed the market significantly in the last one year, generating returns in excess of 50%.

Apart from Deerfield, Justin John Ferayorni’s Tamarack Capital Management is also bullish on Endologix, Inc. (NASDAQ:ELGX). In the second quarter of 2014, it increased its stake in the company by 67% to 2.38 million shares. Endologix, Inc. (NASDAQ:ELGX) also features as a prominent pick of Donald Chiboucis’ Columbus Circle Investors, which as of June 30, 2014 owns 1.35 million shares.

Endologix, Inc. (NASDAQ:ELGX) is a $760 million market cap company that manufactures minimally invasive treatments for aortic disorders. The company expects global revenues for the fiscal year 2014 of in the range of $145 million to $148 million, which represents a growth of  10% to 12% over the revenues it reported for 2013. It also expects the net loss per share to be in the range of $0.37 to $0.43. Most analysts and brokerages are positive on the stock with average recommendation being ‘Overweight’ and average target price amounting to $15.17 per share.

Deerfield Management is life sciences focused fund, which means it watches closely any development in that sector and bets its money only when it is thoroughly convinced. A hedge fund with $5 billion in management has several resources, which an average investor doesn’t. However, an average investor can make similar returns, if they track the activity of these funds and emulate their strategies.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!